GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of SURPASS — 12 things I got wrong before I got it right — 48 comments in the full submission. View in context.
3k
c/trialwatch·submitted 2 years ago by u/hsa_math

SURPASS — 12 things I got wrong before I got it right

Readoutbranch of 6 comments

Thinking out loud about this: SURPASS — 12 things I got wrong before I got it right. Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence. Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was…

Read the full submission and all 48 comments →

This branch

6 comments, started 2 years ago
u/marit_laurent50 points·2 years ago

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

replysharereportpermalink
u/blunt_coldbox_notes25 points·2 years ago

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

replysharereportpermalink
u/britta_boateng27 points·2 years ago

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

replysharereportpermalink
u/ferran_dahlberg15 points·2 years ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink
u/alcohol_aversion4 points·2 years ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink
u/milos_trevino2 points·2 years ago

How long was the randomised phase before any extension?

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →